Cytokinetics (CYTK) Stock Forecast & Price Target

Compare

1,058 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

CYTK Analyst Ratings

Strong Buy

16 Buy

2 Hold

0 Sell

Based on 18 analysts giving stock ratings to

Cytokinetics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

CYTK Stock 12 Month Forecast

Average Price Target

$76.07

▲(137.72%Upside)

Based on 18 Wall Street analysts offering 12 month price targets for Cytokinetics in the last 3 months. The average price target is $76.07 with a high forecast of $120.00 and a low forecast of $41.00. The average price target represents a 137.72% change from the last price of $32.00.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"36":"$36","121":"$121","57.25":"$57.3","78.5":"$78.5","99.75":"$99.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":120,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$120.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":76.07,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$76.07</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":41,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$41.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[36,57.25,78.5,99.75,121],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Nov<br/>2024","9":"Feb<br/>2025","12":"May<br/>2025","25":"May<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,42.92,48.84923076923077,54.77846153846154,60.70769230769231,66.63692307692308,72.56615384615385,78.49538461538461,84.42461538461538,90.35384615384615,96.28307692307692,102.21230769230769,108.14153846153846,114.07076923076923,{"y":120,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,42.92,45.47,48.02,50.57,53.12,55.67,58.22,60.769999999999996,63.31999999999999,65.87,68.41999999999999,70.97,73.52,{"y":76.07,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,42.92,42.77230769230769,42.62461538461539,42.47692307692308,42.32923076923077,42.181538461538466,42.033846153846156,41.886153846153846,41.738461538461536,41.59076923076923,41.44307692307692,41.29538461538461,41.14769230769231,{"y":41,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":63.37,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.51,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":54.7,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.91,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.08,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":52.6,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":51.82,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50.63,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.04,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":49.46,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.5,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 49,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.92,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 58,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$120.00

Average Price Target$76.07

Lowest Price Target$41.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

TipRanks AITipRanks

Not Ranked

TipRanks

$28

Sell

-12.50%

Downside

Reiterated

05/15/25

Cytokinetics faces significant financial and operational challenges impacting its overall stock score. The company struggles with negative profitability, high leverage, and negative cash flows. Technical indicators show bearish trends, and valuation metrics reflect financial strain. While the earnings call highlights some positive developments, the overall sentiment is mixed due to heightened expenses and approval delays. These factors contribute to a low overall stock score, suggesting caution for potential investors.

Gena WangBarclays

Barclays

$53

Buy

65.63%

Upside

Reiterated

05/30/25

Barclays Remains a Buy on Cytokinetics (CYTK)

Salim SyedMizuho Securities

Mizuho Securities

$103→$84

Buy

162.50%

Upside

Reiterated

05/29/25

Mizuho Securities Remains a Buy on Cytokinetics (CYTK)

James CondulisStifel Nicolaus

Stifel Nicolaus

$80→$87

Buy

171.88%

Upside

Reiterated

05/26/25

Stifel Nicolaus Sticks to Its Buy Rating for Cytokinetics (CYTK)

Joseph PantginisH.C. Wainwright

H.C. Wainwright

$120

Buy

275.00%

Upside

Reiterated

05/19/25

Promising SEQUOIA-HCM Study Data Justifies Buy Rating for Cytokinetics

Srikripa DevarakondaTruist Financial

Truist Financial

―

Buy

―

Reiterated

05/14/25

Analysts Offer Insights on Healthcare Companies: Y-Mabs Therapeutics (NASDAQ: YMAB), Claritev (NYSE: CTEV) and Cytokinetics (NASDAQ: CYTK)

Jason ZemanskyBank of America Securities

Bank of America Securities

$45

Hold

40.63%

Upside

Reiterated

05/13/25

Cytokinetics' MAPLE Trial Results: Hold Rating Amid Uncertainties in Secondary Outcomes and Market Adoption

Tessa RomeroJ.P. Morgan

J.P. Morgan

―

Buy

―

Reiterated

05/13/25

Promising Phase 3 Results for Aficamten Boost Cytokinetics' Market Position in Hypertrophic Cardiomyopathy Treatment

Serge BelangerNeedham

Needham

$72

Buy

125.00%

Upside

Reiterated

05/13/25

Cytokinetics' Aficamten Gains Competitive Edge with Successful Phase 3 Study, Strengthening Market Position

Maxwell SkorMorgan Stanley

Morgan Stanley

$65

Buy

103.13%

Upside

Reiterated

05/13/25

Cytokinetics' Promising Phase 3 Trial Results and Market Potential Justify Buy Rating

Roanna RuizLeerink Partners

Leerink Partners

―

Buy

―

Reiterated

05/13/25

Buy Rating for Cytokinetics Driven by Promising Phase 3 Results of Aficamten in Hypertrophic Cardiomyopathy

Cory KasimovEvercore ISI

Evercore ISI

$65→$60

Buy

87.50%

Upside

Reiterated

05/07/25

Cytokinetics (CYTK) PT Lowered to $60 at Evercore ISIEvercore ISI analyst Cory Kasimov lowered the price target on Cytokinetics (NASDAQ: CYTK) to $60.00 (from $65.00) while maintaining a Outperform rating.

Yasmeen RahimiPiper Sandler

Piper Sandler

$107

Buy

234.38%

Upside

Reiterated

05/07/25

Cytokinetics (CYTK) Gets a Buy from Piper Sandler

Jason ButlerCitizens JMP

Citizens JMP

$78

Buy

143.75%

Upside

Reiterated

05/07/25

Citizens JMP reiterates Market Outperform Rating on Cytokinetics (CYTK)Citizens JMP analyst Jason Butler reiterated a Market Outperform rating and $78.00 price target on Cytokinetics (NASDAQ: CYTK).

David LebowitzCiti

Citi

$86→$80

Buy

150.00%

Upside

Reiterated

05/06/25

Cytokinetics price target lowered to $80 from $86 at CitiCytokinetics price target lowered to $80 from $86 at Citi

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

TipRanks AITipRanks

Not Ranked

TipRanks

$28

Sell

-12.50%

Downside

Reiterated

05/15/25

Gena WangBarclays

Barclays

$53

Buy

65.63%

Upside

Reiterated

05/30/25

Barclays Remains a Buy on Cytokinetics (CYTK)

Salim SyedMizuho Securities

Mizuho Securities

$103→$84

Buy

162.50%

Upside

Reiterated

05/29/25

Mizuho Securities Remains a Buy on Cytokinetics (CYTK)

James CondulisStifel Nicolaus

Stifel Nicolaus

$80→$87

Buy

171.88%

Upside

Reiterated

05/26/25

Stifel Nicolaus Sticks to Its Buy Rating for Cytokinetics (CYTK)

Joseph PantginisH.C. Wainwright

H.C. Wainwright

$120

Buy

275.00%

Upside

Reiterated

05/19/25

Promising SEQUOIA-HCM Study Data Justifies Buy Rating for Cytokinetics

Srikripa DevarakondaTruist Financial

Truist Financial

―

Buy

―

Reiterated

05/14/25

Analysts Offer Insights on Healthcare Companies: Y-Mabs Therapeutics (NASDAQ: YMAB), Claritev (NYSE: CTEV) and Cytokinetics (NASDAQ: CYTK)

Jason ZemanskyBank of America Securities

Bank of America Securities

$45

Hold

40.63%

Upside

Reiterated

05/13/25

Cytokinetics' MAPLE Trial Results: Hold Rating Amid Uncertainties in Secondary Outcomes and Market Adoption

Tessa RomeroJ.P. Morgan

J.P. Morgan

―

Buy

―

Reiterated

05/13/25

Promising Phase 3 Results for Aficamten Boost Cytokinetics' Market Position in Hypertrophic Cardiomyopathy Treatment

Serge BelangerNeedham

Needham

$72

Buy

125.00%

Upside

Reiterated

05/13/25

Cytokinetics' Aficamten Gains Competitive Edge with Successful Phase 3 Study, Strengthening Market Position

Maxwell SkorMorgan Stanley

Morgan Stanley

$65

Buy

103.13%

Upside

Reiterated

05/13/25

Cytokinetics' Promising Phase 3 Trial Results and Market Potential Justify Buy Rating

Roanna RuizLeerink Partners

Leerink Partners

―

Buy

―

Reiterated

05/13/25

Buy Rating for Cytokinetics Driven by Promising Phase 3 Results of Aficamten in Hypertrophic Cardiomyopathy

Cory KasimovEvercore ISI

Evercore ISI

$65→$60

Buy

87.50%

Upside

Reiterated

05/07/25

Yasmeen RahimiPiper Sandler

Piper Sandler

$107

Buy

234.38%

Upside

Reiterated

05/07/25

Cytokinetics (CYTK) Gets a Buy from Piper Sandler

Jason ButlerCitizens JMP

Citizens JMP

$78

Buy

143.75%

Upside

Reiterated

05/07/25

Citizens JMP reiterates Market Outperform Rating on Cytokinetics (CYTK)Citizens JMP analyst Jason Butler reiterated a Market Outperform rating and $78.00 price target on Cytokinetics (NASDAQ: CYTK).

David LebowitzCiti

Citi

$86→$80

Buy

150.00%

Upside

Reiterated

05/06/25

Cytokinetics price target lowered to $80 from $86 at CitiCytokinetics price target lowered to $80 from $86 at Citi

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Cytokinetics

1 Month

xxx

Success Rate

10/15 ratings generated profit

Average Return

+11.31%

reiterated a xxx

rating 23 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 66.67% of your transactions generating a profit, with an average return of +11.31% per trade.

3 Months

xxx

Success Rate

9/19 ratings generated profit

Average Return

+10.17%

reiterated a xxx

rating yesterday

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 47.37% of your transactions generating a profit, with an average return of +10.17% per trade.

1 Year

Salim SyedMizuho Securities

Success Rate

31/50 ratings generated profit

Average Return

+25.83%

reiterated a buy rating 7 days ago

Copying Salim Syed's trades and holding each position for 1 Year would result in 62.00% of your transactions generating a profit, with an average return of +25.83% per trade.

2 Years

xxx

Success Rate

29/50 ratings generated profit

Average Return

+21.83%

reiterated a xxx

rating 7 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 58.00% of your transactions generating a profit, with an average return of +21.83% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

CYTK Analyst Recommendation Trends

Rating

Jan 25

Feb 25

Mar 25

Apr 25

May 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, CYTK has received 58 Buy Ratings, 8 Hold Ratings, and 0 Sell Ratings. CYTK average Analyst price target in the past 3 months is 76.07.

Each month's total comprises the sum of three months' worth of ratings.

CYTK Financial Forecast

CYTK Earnings Forecast

Next quarter’s earnings estimate for CYTK is -$1.42 with a range of -$1.60 to -$1.24. The previous quarter’s EPS was -$1.36. CYTK beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.04% of the time in the same period. In the last calendar year CYTK has Outperformed its overall industry.

CYTK Sales Forecast

Next quarter’s sales forecast for CYTK is $2.01M with a range of $0.00 to $15.00M. The previous quarter’s sales results were $1.58M. CYTK beat its sales estimates 25.00% of the time in past 12 months, while its overall industry beat sales estimates 47.46% of the time in the same period. In the last calendar year CYTK has Outperformed its overall industry.

CYTK Stock Forecast FAQ

What is CYTK’s average 12-month price target, according to analysts?

Based on analyst ratings, Cytokinetics’s 12-month average price target is 76.07.

What is CYTK’s upside potential, based on the analysts’ average price target?

Cytokinetics has 137.72% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is CYTK a Buy, Sell or Hold?

Cytokinetics has a consensus rating of Strong Buy which is based on 16 buy ratings, 2 hold ratings and 0 sell ratings.

What is Cytokinetics’s price target?

The average price target for Cytokinetics is 76.07. This is based on 18 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $120.00 ,the lowest forecast is $41.00. The average price target represents 137.72% Increase from the current price of $32.

What do analysts say about Cytokinetics?

Cytokinetics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 18 Wall Streets Analysts.

How can I buy shares of CYTK?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Cytokinetics (CYTK) Stock Forecast & Price Target

CYTK Analyst Ratings

CYTK Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Cytokinetics

CYTK Analyst Recommendation Trends

CYTK Financial Forecast

CYTK Earnings Forecast

CYTK Sales Forecast

CYTK Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts